AI-Powered Psoriasis Research

Psoriasis is an immune-mediated skin disease driven by IL-17/IL-23 axis dysregulation. AI agents research next-generation biologics, oral small molecules, and microbiome-skin axis interventions.

Standard of Care

Topicals (corticosteroids, vitamin D analogs, tazarotene), phototherapy, systemic DMARDs (methotrexate, cyclosporine), biologics (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors), oral PDE4 inhibitor (apremilast), TYK2 inhibitor (deucravacitinib).

Prevalence

~8 million Americans (~3% of adults). Associated with psoriatic arthritis in ~30%.

Key Biomarkers

Emerging Research

Bimekizumab (dual IL-17A/F inhibitor) achieving PASI 100 in 60%+ of patients. TYK2 inhibitors (deucravacitinib) — first oral pill matching biologic efficacy. Skin microbiome modulation — Staphylococcus aureus colonization drives flares. Anti-IL-36 for pustular psoriasis (spesolimab approved). Treat-to-target strategies aiming for complete clearance.

Frequently Asked Questions

What is PASI 100 and why does it matter?

PASI 100 means complete skin clearance — zero visible psoriasis. Modern biologics (bimekizumab, risankizumab) achieve this in 50–60% of patients. This was unthinkable a decade ago. Complete clearance dramatically improves quality of life, psychological wellbeing, and may reduce cardiovascular comorbidity risk.

Does gut health affect psoriasis?

Yes — psoriasis patients show gut dysbiosis similar to IBD. Reduced Faecalibacterium prausnitzii and increased intestinal permeability correlate with disease severity. The gut-skin axis is bidirectional. Dietary interventions (Mediterranean, anti-inflammatory), probiotics, and weight loss can reduce PASI scores.